Indacaterol
Other / unclassified targets ADRB2 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ARCAPTA NEOHALER | — | 2011-07-01 | fda.gov ↗ |
| Approved | EU (EMA) | Oslif Breezhaler | — | 2009-11-29 | europa.eu ↗ |
Trials 109 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05288075 | Feb → Jun 2022 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT04856098 | May → Sep 2021 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02573155 | Oct 2015 → Aug 2016 | asthma, chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01263808 | Apr → Aug 2008 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00410501 | Dec 2006 → ? | — | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00416702 | Nov 2006 → Mar 2008 | liver disorder | Novartis | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06841640 | Jan → May 2025 | chronic obstructive pulmonary disease | AeroRx Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00422552 | Sep 2006 → ? | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT06035393 | Jan 2024 → Feb 2025 | chronic obstructive pulmonary disease | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT06619210 | Jan 2022 → May 2023 | chronic obstructive pulmonary disease | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04589663 | Jun 2021 → Apr 2022 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03257995 | Sep 2017 → Jan 2018 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01959412 | Nov 2013 → Mar 2014 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01845623 | Aug → Dec 2013 | asthma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01636076 | Nov 2012 → Sep 2013 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01609478 | Aug 2012 → Jul 2013 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01484197 | Nov 2011 → May 2012 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01156844 | Mar → Jul 2010 | chronic asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01012739 | Oct 2009 → Mar 2010 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00941798 | Jul 2009 → May 2011 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00927901 | Jun → Nov 2009 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00636961 | Feb → Aug 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00605306 | Jan → Apr 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00557440 | Nov 2007 → Apr 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00558285 | Nov 2007 → Jul 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00556673 | Oct 2007 → Apr 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00557466 | Oct 2007 → May 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00545272 | Oct 2007 → Apr 2008 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00531050 | Aug 2007 → Jun 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00403845 | Dec 2006 → Oct 2007 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00403754 | Nov 2006 → Nov 2007 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00129831 | Sep 2004 → Sep 2005 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00098228 | Jul → Dec 2004 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT02693769 | Jul → Oct 2016 | asthma | Mundipharma Research Limited | Terminated | No outcome recorded |
| Phase 2/3 | NCT00463567 | Apr 2007 → Aug 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 2/3 | NCT00403637 | Nov 2006 → Feb 2007 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2/3 | NCT00396604 | Oct 2006 → Jan 2007 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 343 trials | ||||||
| Phase 3 | NCT05776927 | May 2026 → Dec 2028 expected | asthma | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06643078 | Dec 2023 → May 2025 | chronic obstructive pulmonary disease | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05562466 | May 2023 → Feb 2028 expected | asthma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT04206761 | Dec 2021 → Jul 2022 | asthma | Dr. Grace Parraga | Withdrawn | No outcome recorded |
| Phase 3 | NCT03158311 | Feb 2018 → Jul 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02892344 | Jan 2017 → Nov 2018 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02554786 | Dec 2015 → Nov 2018 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02571777 | Dec 2015 → Jun 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02598505 | Sep 2015 → Nov 2016 | heart failure | Centro Cardiologico Monzino | Completed | No outcome recorded |
| Phase 3 | NCT02487498 | Jul 2015 → Sep 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01782326 | Jul 2013 → Sep 2015 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01778062 | Feb 2013 → Sep 2014 | pulmonary tuberculosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01709903 | Nov 2012 → Feb 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01315249 | Mar 2011 → Mar 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01232894 | Mar 2011 → May 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01294787 | Feb → Nov 2011 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01285492 | Jan 2011 → Sep 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01120691 | Apr 2010 → Jul 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01120717 | Apr 2010 → Dec 2011 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01089127 | Mar → Jul 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01079130 | Feb → Jul 2010 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01068600 | Jan → Jun 2010 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01072448 | Jan → Jul 2010 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01012765 | Nov 2009 → Jan 2011 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00999908 | Oct 2009 → Mar 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00900731 | Jun 2009 → Mar 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00877383 | Apr 2009 → Feb 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00876694 | Mar 2009 → Oct 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00845728 | Mar 2009 → Jul 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00846586 | Mar 2009 → Mar 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00821093 | Jan → Oct 2009 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00794157 | Nov 2008 → Oct 2009 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00792805 | Nov 2008 → Feb 2010 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00677807 | May 2008 → Mar 2009 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00620022 | Apr 2008 → Jan 2009 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00669617 | Apr → Aug 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00624286 | Feb → Jul 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00615459 | Feb → Dec 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00615030 | Jan → Jul 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00622635 | Jan → Jul 2008 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00567996 | Nov 2007 → Jan 2009 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00529529 | Sep 2007 → Aug 2008 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00393458 | Oct 2006 → Jul 2008 | chronic obstructive pulmonary disease | Novartis | Completed | No outcome recorded |
| Phase 426 trials | ||||||
| Phase 4 | NCT04509661 | Sep 2020 → Jun 2024 | idiopathic bronchiectasis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT03662711 | Nov 2018 → Oct 2022 | chronic obstructive pulmonary disease | Università degli Studi di Ferrara | Terminated | No outcome recorded |
| Phase 4 | NCT02953041 | Oct 2016 → Jan 2017 | asthma | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT02567214 | Jun 2016 → Nov 2018 | chronic obstructive pulmonary disease | Laval University | Completed | No outcome recorded |
| Phase 4 | NCT02872090 | Mar 2016 → Jun 2021 | chronic obstructive pulmonary disease | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 4 | NCT02516592 | Oct 2015 → May 2017 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02547558 | Oct 2015 | chronic obstructive pulmonary disease | Hospital Clinic of Barcelona | Unknown | No outcome recorded |
| Phase 4 | NCT02442206 | May 2015 → Apr 2017 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02418468 | Apr 2015 → Apr 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02233543 | Nov 2014 → Jun 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02202616 | Aug 2014 → Apr 2017 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02055352 | May 2014 → Jan 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01985334 | Feb 2014 → Apr 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01996124 | Nov 2013 → Oct 2014 | chronic obstructive pulmonary disease, heart failure | University of Milan | Completed | No outcome recorded |
| Phase 4 | NCT01727024 | Apr 2013 → Nov 2015 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02473237 | Apr 2013 → Jun 2015 | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT02566031 | Mar 2013 → Jun 2018 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01693003 | Mar → Oct 2013 | chronic obstructive pulmonary disease | Irmandade Santa Casa de Misericórdia de Porto Alegre | Completed | No outcome recorded |
| Phase 4 | NCT01794780 | Feb 2013 → May 2015 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01715311 | Nov 2012 → Sep 2013 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT05506865 | Sep 2012 → Jan 2016 | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT01555138 | Feb 2012 → Feb 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01543828 | Jan → Mar 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01377428 | Sep 2011 → Feb 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT01437748 | Aug 2011 → Sep 2014 | chronic obstructive pulmonary disease | University of Milan | Completed | No outcome recorded |
| Phase 4 | NCT01272362 | Apr 2010 → May 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07541378 | Mar 2024 → Feb 2025 | chronic obstructive pulmonary disease | Medical University of Bialystok | Suspended | No outcome recorded |
| — | NCT06067100 | Jan 2024 → Jul 2026 overdue | — | Morten Hostrup, PhD | Recruiting | No outcome recorded |
| — | NCT06077019 | Oct 2023 → Jul 2026 overdue | — | Morten Hostrup, PhD | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 24 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02059434 Comparator | Sep 2013 → Oct 2014 | asthma, chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00624702 Comparator | Feb → Sep 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02892019 Comparator | Apr 2017 → Jun 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01498081 Comparator | Mar → Oct 2012 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01425814 Comparator | Aug 2011 → Mar 2012 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00570778 Comparator | Dec 2007 → Sep 2008 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT04259164 Background | Sep 2020 → Dec 2022 | allergic asthma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 3 | NCT03379233 Background | Jul 2018 → Jan 2019 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02867761 Comparator | Aug 2017 → Jul 2021 | chronic obstructive pulmonary disease | University of Michigan | Completed | No outcome recorded |
| Phase 3 | NCT02257385 Comparator | Oct 2014 → May 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02165826 Background | May 2014 → Sep 2015 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01996319 Comparator | Apr 2014 → Feb 2015 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01712516 Comparator | Dec 2012 → Feb 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01727141 Comparator | Nov 2012 → Feb 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01699685 Comparator | Nov 2012 → Jun 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01682863 Comparator | Oct 2012 → Jun 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01697696 Comparator | Oct 2012 → Nov 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01529632 Comparator | May → Dec 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01604278 Comparator | May 2012 → Jan 2013 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01202188 Comparator | Sep 2010 → Feb 2012 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06282861 Comparator | Feb 2024 → Jan 2025 | chronic obstructive pulmonary disease | Fundacio Privada Mon Clinic Barcelona | Terminated | No outcome recorded |
| Phase 4 | NCT02039011 Comparator | Feb 2014 → Jul 2016 | asthma | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT01377051 Comparator | May → Aug 2011 | cardiac rhythm disease, chronic obstructive pulmonary disease | University of Milan | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07058259 Background | Nov 2024 → Jun 2025 overdue | chronic obstructive pulmonary disease | Istanbul Medeniyet University | Active not recruiting | No outcome recorded |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 140 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | indacaterol | “The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6 μg twice daily (b.i.d.),...” PMID 27215502 ↗ Mar 2016121“Dual Therapy (LABA + LAMA): Patients receive a long-acting beta-agonist (LABA) such as Formoterol, Salmeterol, Olodaterol, Vilanterol, or Indacaterol, in combination with a...” NCT07058259 ↗ “The investigators will compare the reduction in Borg dyspnea score during the 3-min constant rate shuttle walking test after 3 weeks of indacaterol 110 µg/Glycopyrronium 50 µg...” NCT02567214 ↗ “QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium...” PMID 23867808 ↗ Jul 2013 “We randomly assigned participants (1:1) to either receive a combined inhaled dual bronchodilator containing the LABA indacaterol (110 μg as maleate salt) plus the LAMA...” PMID 29477448 ↗ Feb 2018 “Seventy patients (aged ≥40 years, Global initiative for chronic Obstructive Lung Disease Stage II/III) were randomised (1:1:1:1:1:1) to single doses of abediterol 0.625, 2.5, 5...” PMID 27439370 ↗ Jul 2016 “AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) under development for...” NCT06841640 ↗ “HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg,...” NCT06643078 ↗ “The purpose of this study was to determine whether a fixed dose combination of indacaterol and glycopyrronium (QVA149) has an impact on night-time blood oxygen levels in...” NCT02233543 ↗ “Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled,...” PMID 27301417 ↗ Jun 2016 “Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics:...” NCT02165826 ↗ “Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.” PMID 30074294 ↗ Aug 2018 “PURPOSE: To compare the efficacy and safety of two long-acting dual bronchodilator combinations: indacaterol/glycopyrrolate (IND/GLY) versus umeclidinium/vilanterol (UMEC/VI).” PMID 28993871 ↗ Oct 2017 “QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate.” NCT04206761 ↗ “once-daily QVA149 (fixed-dose combination of indacaterol 110 μg and glycopyrronium 50 μg), glycopyrronium 50 μg, or tiotropium 18 μg” PMID 24429126 ↗ Apr 2013 “Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler” NCT03379233 ↗ “QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®” NCT05776927 ↗ “HL231 261 µg/141 µg demonstrated peak concentration (Cmax) of indacaterol and glycopyrronium at 86% and 54% of Ultibro®” PMID 41229760 ↗ Oct 2025 “A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture” NCT01845623 ↗ “a fixed-dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg” NCT00941798 ↗ “Inhaled indacaterol/glycopyrronium fixed-dose combination (IND/GLY) is approved in over 80 countries” PMID 27715335 ↗ Aug 2016 “QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device” NCT01636076 ↗ “QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1” NCT01285492 ↗ “free combination of indacaterol maleate (IND) and glycopyrronium bromide (GLY)” PMID 28077140 ↗ Jan 2017 “the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily” PMID 27181606 ↗ May 2016 “Indacaterol-Glycopyrronium (110ug/50ug QD inhalation) for one year.” NCT04509661 ↗ “Indacaterol acetate / glycopyrronium bromide / mometasone furoate” NCT03158311 ↗ “QMF149 (Indacaterol Acetate / Mometasone Furoate)” NCT05562466 ↗ “a long-acting β2-agonist (indacaterol)” PMID 26177074 ↗ Nov 2015 “Mometasone / Indacaterol” NCT04259164 ↗ “Indacaterol” NCT03662711 ↗ |
| Known as | AERO-001 | “AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) under development for...” NCT06841640 ↗ |
| Known as | Arcapta neohaler | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Hirobriz breezhaler | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | IND | “The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6 μg twice daily (b.i.d.),...” PMID 27215502 ↗ Mar 20163“GLOW6 evaluated the efficacy and safety of once-daily coadministration of the long-acting β2-agonist indacaterol (IND) and the long-acting muscarinic antagonist glycopyrronium...” PMID 24596459 ↗ Feb 2014 “ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with challenge performed after first and last doses at trough.” PMID 28665534 ↗ Aug 2017 “free combination of indacaterol maleate (IND) and glycopyrronium bromide (GLY)” PMID 28077140 ↗ Jan 2017 |
| Known as | Indacaterol (as maleate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Indacaterol acetate | “Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9” NCT04589663 ↗4“QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device” NCT02571777 ↗ “QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device” NCT01636076 ↗ “Indacaterol acetate/Mometasone furoate” NCT02892344 ↗ |
| Known as | Indacaterol maleate | “This study aimed to establish optimal dosage of nebulized HL231 inhalation solution (HL231), comparable to Ultibro® (110 µg indacaterol maleate/50 µg glycopyrronium bromide),...” PMID 41229760 ↗ Oct 202510“Indacaterol maleate, long-acting beta2-agonist (LABA). Administered as 110 μg, 1 capsule inhaled once daily via Breezhaler device for 28 days in combination with glycopyrronium.” NCT07541378 ↗ “fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF)” PMID 25649209 ↗ Feb 2015 “Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler” NCT03379233 ↗ “Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.” NCT01377051 ↗ “Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.” NCT01012739 ↗ “Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients” NCT02442206 ↗ “Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.” NCT01529632 ↗ “free combination of indacaterol maleate (IND) and glycopyrronium bromide (GLY)” PMID 28077140 ↗ Jan 2017 “Drug: Indacaterol maleate and glycopyrronium bromide” NCT04856098 ↗ “Drug: Indacaterol maleate” NCT01437748 ↗ |
| Known as | Indacaterol maleate component of qva-149 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Indacaterol maleate component of ultibro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Indacaterol maleate component of utibron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Indacterol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Indacterol maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | Onbrez | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06282861 ↗ |
| Known as | Onbrez Breezhaler | “Study of the Predictive Value of Airway Obstruction Reversibility on the Effectiveness of Indacaterol (Onbrez® Breezhaler ®) 150 mcg Once Daily in Patients With Moderate to Severe COPD” NCT01272362 ↗ |
| Known as | Oslif breezhaler | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | QAB-149-AFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Known as | QAB149 | “Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler” NCT03379233 ↗9“Indacaterol (QAB149)” NCT00410501 ↗ “Indacaterol (QAB149)” NCT00422552 ↗ “indacaterol (QAB149)” NCT01202188 ↗ |
| Known as | QABI49 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1095777 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL1095777 ↗1“β2-adrenoceptor agonist” PMID 21184620 ↗ 2011 |
| Modality | Other / unclassified | “once-daily long-acting β2 agonist” PMID 27812637 ↗ Sep 2016 |
| Route | Inhaled | “delivery via a multiple dose inhaler” NCT00098228 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL1095777 ↗ |